Zalifrelimab, CAS 2148321-69-9

Product Description: Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771. /[2]Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13(4):e0191926.

CAS Number: 2148321-69-9

Molecular Weight: N/A

Compound Purity: 98.28

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CTLA-4

• Artikelnummer: MEXHY-P99514-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99514-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated